Genentech, Inc.

F. Hoffmann-la Roche Ag

Emanuela Gancia

Eileen Mary Seward

Lewis J Gazzard

Timothy Heffron

Andrew Madin

Bryan K Chan

Sushant Malhotra

Michael Lainchbury

BinQing Wei

Craig Stivala

Jun Liang

Benjamin Fauber

Rohan V Mendonca

Kin Chiu Fong

Monique Bodil Van Niel

Michael Siu

Graham Elgin Jones

Naomi S Rajapaksa

Stuart Ward

Christopher Hurley

Weiru Wang

Aihe Zhou

Joseph P Lyssikatos

Huifen Chen

Robert Andrew Heald

Hazel Joan Dyke

James John Crawford

Andrew Peter Cridland

Simon Charles Goodacre

Calum MacLeod

Richard Leonard Elliott

Karen Williams

Binqing Wei

Daniel P Sutherlin

Stephen Colin Price

Brian Salvatore Safina

Steven T Staben

Wendy Lee

Thomas David Pallin

David Edward Clark

Nadia M Ahmad

Terry Aaron Panchal

Jason R Zbieg

Calum Macleod

Yonghan Hu

Matthew W Cartwright

John Tellis

David Favor

Andrew Good

Joy Drobnick

Olivier Rene

Paul Winship

David Robert Vesey

Alberto Gobbi

Tammy Ladduwahetty

Aijun Lu

Baihua Hu

Malcolm Huestis

Blake Daniels

Sarah Bronner

Jonathan Killen

Samuel S Kintz

Simon Gaines

Charles Ellwood

Michael D Ryan

Toby Jonathan Blench

Terry Kellar

Patrick Cyr

Bohdan Waszkowycz

Elsa Amandine Dechaux

Toby Matthew Grover Mullins

Philip Jackson

Tammy Laddywahetty

Naomi Rajapaksa

John C Tellis

David Vesey

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and uses thereof

Naphthyridine compounds and uses thereof

The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.

Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof

Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.

Azaindoles as inhibitors of HPK1

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinolines as inhibitors of HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, p, q A, B, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Pyridazine derivatives as RORc modulators

Compounds of formula I: or pharmaceutical salts thereof,

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X, X, X, X, Y, Z, A, Het, R, R, R, R, RR, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Aryl sultam derivatives as RORc modulators

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X, X, X, X, Y, Z, A, R, R, R, R, RR, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n, p, q, r, A, W, X, X, X, X, Y, Z, R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R, Rand Rare as defined herein.

Methods of use of diazacarbazoles for treating cancer

Growing community of inventors

Harlow, United Kingdom

Emanuela Gancia